The contest to find a better migraine drug in the calcitonin gene-related peptide (CGRP) pathway had fallout for Alder Biopharmaceuticals Inc. as the company unveiled what were called "strongly positive" phase III Promise 1 data – despite a hefty placebo response – with eptinezumab, its lead product candidate to prevent such headaches.